Posted 1st November 2017 by Jane Williams
Whether in a research or clinical lab, digital pathology holds a great deal of promise for all stakeholders. Earlier this year, a digital pathology platform obtained FDA clearance for whole slide imaging, thereby increasing both awareness and applicability of digital pathology. It may, however, be difficult for hospitals and laboratories to justify the acquisition costs of digital pathology platforms if one only looks on the surface. Matt Houliston from Definiens looks at the workflow and economic benefits of adopting digital pathology beyond the perhaps more obvious clinical benefits.
Posted 20th October 2017 by Jane Williams
There has been a steady increase in the adoption of Quantitative Image Analysis (QIA) for diagnostic purposes, especially for breast biomarker testing.
Posted 11th October 2017 by Jane Williams
An extensively used technique for evaluating the expression of tissue antigens and their behaviour is known as immunohistochemistry (IHC). In this technique, the primary antibody raised against the specific antigen and a secondary antibody against the primary one is used for detecting specific targets of clinical relevance. IHC has the greatest impact on diagnostic pathology compared to any other technique. Although modern methods of flow cytometry and molecular diagnosis have also contributed enormously, IHC still remains the most relevant solution for various pathological diagnostic problems.
Posted 22nd September 2017 by Jane Williams
With the recent shift in the industry as the result of this decision, a common question is “What lies in store for digital pathology system manufacturers in the wake of the FDA granting Philips’ de novo classification request for its IntelliSite device?”
Posted 15th September 2017 by Jane Williams
In 2017, technological advances in cloud computing and artificial intelligence has pathology positioned to become one of the most talked about medical fields in healthcare.
Posted 4th September 2017 by Jane Williams
For the past decade-plus, the digital pathology industry, pathologists and regulators have had conferences, meetings, and association and society gatherings to figure out how to ensure safe and effective use of whole slide imaging. Early meetings focused on pixels and colours. Subsequent discussions were about study designs and clinical validation.
Posted 21st August 2017 by Jane Williams
The three-dimensional reconstruction and examination of tissue at microscopic resolution have significant potential to enhance the study of normal and disease processes, particularly those involving structural changes or those in which the spatial relationship of disease features is important. Its application to, or combination with techniques such as immunohistochemistry (IHC) or in situ hybridization, adds further value by allowing understanding of additional phenotypic or functional information.
Posted 16th August 2017 by Jane Williams
Digitization paves the way for machine learning
With the first FDA approval for primary diagnosis now being a fact, together with several European labs performing the majority of their review digitally, the digitization of pathology has sped up and is now in many labs’ plans.